Skip to main content

Fiscal Wizard · Single-issue tearsheet

JNJ / Aug 31, 2026 Run #19052

JNJ

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Composite verdict

B 72.1 / 100
Bullish setup · Trend Following 11 drivers · 3 gates blocking
  • Relative Strength vs SPY
  • Sector Relative Strength
  • Fibonacci Retracement
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 3rd of 9 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 22 signals0% Bear
Momentum Bullish 99Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -81%
Asset value $33.84Earnings power value $72.88Price $266.39

Priced above its no-growth earnings power value ($72.88/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

44.3 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
Greenblatt ROC 86
Cash Conversion Cycle 0
OCF to Net Income 83
Inventory Turnover 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Relative Strength vs SPY, Sector Relative Strength, Fibonacci Retracement); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Vortex Signal 86
Relative Strength vs SPY 86
Sector Relative Strength 86

Risk Gates

3 blocking 5 caution

3 guards active, 18 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for JNJ.